Status:

TERMINATED

Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

Lead Sponsor:

Pfizer

Conditions:

Chronic Pancreatitis

Eligibility:

All Genders

18-99 years

Phase:

PHASE2

Brief Summary

Tanezumab is effective in reducing the pain associated with chronic pancreatitis.

Detailed Description

On 23 Dec 2010 the FDA imposed a clinical halt for anti-NGF compounds due to safety reasons, ie, a case of osteonecrosis which occurred in relation to an anti-NGF compound of another company. All indi...

Eligibility Criteria

Inclusion

  • Adult male or female
  • Written informed consent
  • Diagnosis of chronic pancreatitis based on imaging studies
  • Persistent abdominal pain due to chronic pancreatitis
  • Qualifying pain score during the pre-treatment period
  • Willing to comply with study visit schedule and study requirements including for women of child-bearing potential or male patients with female partners of child-bearing potential, the use of 2 forms of birth control

Exclusion

  • Pregnant women, lactating mothers, women suspected of being pregnant and women who wish to become pregnant during the course of the study
  • Chronic pancreatitis as a complication of pancreatic cancer or acute pancreatic duct obstruction
  • Pancreatic surgery, lithotripsy or endoscopist decompression within 3 months
  • History of alcoholism (within 1 year of screening) or concurrent alcohol abuse
  • History of cancer in the past years
  • Significant cardiac disease within 6 months
  • History, diagnosis or signs and symptoms of significant neurologic disease
  • Disqualifying laboratory values including Hepatitis B or C, HIV and drug test
  • Other medical condition that may interfere with study endpoints or safety of the patient as determined by the Investigator
  • Known history of rheumatoid arthritis
  • Avascular necrosis of the bone
  • History of trauma to a major joint Evidence of osteoarthritis

Key Trial Info

Start Date :

October 13 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 22 2011

Estimated Enrollment :

2 Patients enrolled

Trial Details

Trial ID

NCT01146561

Start Date

October 13 2010

End Date

March 22 2011

Last Update

March 23 2021

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Gastroenterology Group-of Naples

Naples, Florida, United States, 34102-5449

2

Palm Beach Gastroenterology

Wellington, Florida, United States, 33414

3

Digestive Health Specialists

Tupelo, Mississippi, United States, 38801

4

North Mississippi Medical Center

Tupelo, Mississippi, United States, 38801

Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis | DecenTrialz